Pharmaceutical - AstraZeneca, Eli Lilly


Current filters:

AstraZenecaEli Lilly

Popular Filters

Atherothrombotic diseases market to grow to $47 billion in 2022

Atherothrombotic diseases market to grow to $47 billion in 2022


The launch of numerous add-on therapies in the atherothrombotic diseases market (incorporating pharmacotherapies…

AstraZenecaBayerBrilintaCardio-vascularEli LillyevacetrapibGlobalMarkets & MarketingPharmaceuticalXarelto

EU regulator finds no added pancreatic risks for GLP-1 diabetes drugs


Having finalized a review of glucagon-like peptide 1 (GLP-1)-based diabetes therapies, the European Medicines…

AstraZenecaBoehringer IngelheimBristol-Myers SquibbBydureonDiabetesEli LillyEuropeJanuviaMerck & CoNovo NordiskOnglyzaPharmaceuticalRegulationTradjentaVictoza

Research briefs: Lilly's Forteo; Genmab/GSK's Arzerra; AstraZeneca's Symbicort


US drug major Eli Lilly (NYSE: LLY) has reported new data demonstrating that Forteo (teriparatide) significantly…

Anti-Arthritics/RheumaticsArzerraAstraZenecaEli LillyForteoGenmabGlaxoSmithKlineOncologyPharmaceuticalResearchRespiratory and PulmonarySymbicort

STEMI guidelines now recommend AstraZeneca's ticagrelor as first-line treatment option


Anglo-Swedish drug major AstraZeneca (LSE: AZN) said yesterday that ticagrelor, its oral antiplatelet…

AstraZenecaBrilintaBriliqueCardio-vascularEffientEli LillyPharmaceuticalRegulation

AstraZeneca and Bristol-Myers complete diabetes alliance expansion; Lilly revises guidance


Anglo-Swedish drug major AstraZeneca (LSE: AZN) said yesterday that, following Bristol-Myers Squibb's…

AmylinAstraZenecaBiotechnologyBristol-Myers SquibbDiabetesEli LillyFinancialLicensingPharmaceutical

Amylin seduced by $5.3 billion bid from Bristol-Myers; AstraZeneca chips in for share of the action


Having rejected a media reported $22 a share offer from the company earlier this year, US biotech firm…

AmylinAstraZenecaBiotechnologyBristol-Myers SquibbBydureonByettaDiabetesEli LillyMergers & AcquisitionsPharmaceutical

US NIH debuts collaborative program with Pharma to spur therapeutic development


The US National Institutes of Health last week unveiled a collaborative program that will match researchers…

AstraZenecaBiotechnologyEli LillyNorth AmericaPfizerPharmaceuticalResearch

Brazilian acute coronary syndrome drug market set to nearly double to $229 million in 2015


The acute coronary syndrome (ACS) drug market in Brazil will nearly double from $122 million in 2010…

AstraZenecaBrilintaCardio-vascularEffientEli LillyMarkets & MarketingPharmaceuticalSouth America

China’s acute coronary syndrome drug market forecast to grow to nearly $450 million in 2015


The acute coronary syndrome (ACS) drug market in China will grow from $326 million in 2010 to $448 million…

Asia-PacificAstraZenecaBrilintaCardio-vascularEffientEli LillyMarkets & MarketingPharmaceuticalPlavixSanofi

Company Spotlight



Back to top